Litigation Details for Sun Pharmaceutical Industries Ltd. v. Saptalis Pharmaceuticals, LLC (D. Del. 2018)
✉ Email this page to a colleague
Sun Pharmaceutical Industries Ltd. v. Saptalis Pharmaceuticals, LLC (D. Del. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-04-30 |
| Court | District Court, D. Delaware | Date Terminated | 2019-09-04 |
| Cause | 35:271 Patent Infringement | Assigned To | William C. Bryson |
| Jury Demand | None | Referred To | |
| Parties | SUN PHARMACEUTICAL INDUSTRIES LTD. | ||
| Patents | 6,890,957; 9,000,021 | ||
| Attorneys | Charles B. Klein | ||
| Firms | Heyman Enerio Gattuso & Hirzel LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Sun Pharmaceutical Industries Ltd. v. Saptalis Pharmaceuticals, LLC
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Sun Pharmaceutical Industries Ltd. v. Saptalis Pharmaceuticals, LLC (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-06-19 | 108 | Order - -Memorandum and Order | LLC, is the sole owner of U.S. Patent No. 6,890,957 (“the ’957 patent”). Dkt. No. 1, at 3. Plaintiff …Compare ‘957 patent, claim 3 with ’957 patent, claim 4. Saptalis argues that because the patent contains…application that issued as U.S. Patent No. 6,559,187 (“the ’187 patent”). See Dkt. No. 70, at 2; Dkt. …diabetes.” ’957 patent, col. 1, ll. 15–17. Claim 1 is the only independent claim of the ’957 patent. Dkt. No…the drug protected by the ’957 patent. The agency then listed the patent in its publication entitled Approved | External link to document |
| 2019-09-04 | 149 | Judgment | not infringe any asserted claim of U.S. Patent No. 6,890,957. Thus, judgment of noninfringement is entered… counterclaim, asserting invalidity of the ’957 patent, the parties argue that the claim is moot in light… 4 September 2019 1:18-cv-00648 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-09-04 | 150 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,890,957. (Attachments: # 1 … 4 September 2019 1:18-cv-00648 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-07-23 | 173 | Redacted Document | corrected patent information on November 15, 2018, for U.S. Patent No. 6,890,957 (“the ’957 patent”), which…limiting the patent term, Sun submitted Exhibit A to FDA on November 15, 2018 to correct the patent expiration…expiration date listed in the Orange Book for the ’957 patent may be incorrect. After investigating the issue… 4 September 2019 1:18-cv-00648 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-08-26 | 186 | Order - -Memorandum and Order | protected by U.S. Patent No. 6,890,957 (“the ’957 patent”). Dkt. No. 143, at 2. The ’957 patent “relates to…in treating hyperglycemia and/or diabetes.” ’957 patent, col. 1, ll. 1 Saptalis filed…New Drug Application, the agency then listed the patent in the FDA publication entitled Approved Drug …that Saptalis’s ANDA product infringes the ’957 patent. Early in the case, Saptalis filed a motion…present in the only independent claim of the ’957 patent. Dkt. No. 143, at 6. One of those limitations | External link to document |
| 2018-04-30 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,890,957. (sar) (Entered: 04… 4 September 2019 1:18-cv-00648 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
